News & Events
Rebiotix and CoreBiome Collaborate on Evaluating Microbiomes of Patients Treated with Microbiota Restoration Therapy (opens in a new tab)
Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia (opens in a new tab)
Vedanta Biosciences Announces Initiation of Phase 1a/1b Trial for New Drug Class of Rationally-Defined Bacterial Consortia Derived from the Human Microbiome (opens in a new tab)
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy (opens in a new tab)
CARB-X awards up to $5.4M to Vedanta Biosciences to accelerate the development of a novel human microbiome-derived treatment for deadly C. difficile bacterial infections (opens in a new tab)
Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells (opens in a new tab)
Vedanta Biosciences Granted U.S. Patent Broadly Covering Methods of Treatment with Therapeutics Based on Bacterial Spore Fractions of Microbiota Obtained From Human Donors (opens in a new tab)
Vedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia (opens in a new tab)
Vedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University School of Medicine and Leiden University Medical Center (opens in a new tab)
The Airway Microbiome at Birth (2016) (opens in a new tab)
The post The Airway Microbiome at Birth (2016) appeared first on Alveolus Bio .…
Vedanta Biosciences Granted First European Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia (opens in a new tab)
Vedanta Biosciences Granted Third U.S. Patent Covering Methods of Treating Infectious and Allergic Diseases with Bacterial Consortia (opens in a new tab)
Vedanta Biosciences Granted Second U.S. Patent Covering Methods of Treating Autoimmune Disease with Therapeutics Based on Bacterial Consortia (opens in a new tab)
Vedanta Biosciences Granted U.S. Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia (opens in a new tab)
Vedanta Biosciences Announces Collaboration with the NYU Langone Medical Center to Develop Microbiome-Derived Immunotherapies for Cancer (opens in a new tab)
Vedanta Biosciences Closes $50 Million Financing to Advance Microbiome Therapeutics (opens in a new tab)
Vedanta Biosciences Announces License Agreement with RIKEN and other Japanese Institutions for New Immune Boosting Microbiome Technology (opens in a new tab)
Vedanta Biosciences Appoints New Chief Scientific Officer and Expands to New Facility (opens in a new tab)
Defense Secretary Carter Visits Vedanta (opens in a new tab)
Vedanta Biosciences Expands Team with Additions of Head of Preclinical Development and Head of Intellectual Property (opens in a new tab)